Merck KGaA splurges $230M on its pipeline, paying Vertex for a slate of early-stage cancer drugs
With its Big Pharma partner Pfizer in hot pursuit of an approval for their checkpoint inhibitor, the disaster-prone Merck KGaA is splurging on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
